Invention Grant
- Patent Title: Triazine kinase inhibitors
- Patent Title (中): 三嗪激酶抑制剂
-
Application No.: US12670257Application Date: 2008-07-24
-
Publication No.: US08415340B2Publication Date: 2013-04-09
- Inventor: Upender Velaparthi , Peiying Liu , Mark D. Wittman , David R. Langley
- Applicant: Upender Velaparthi , Peiying Liu , Mark D. Wittman , David R. Langley
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Elliott Korsen
- International Application: PCT/US2008/070961 WO 20080724
- International Announcement: WO2009/015254 WO 20090129
- Main IPC: A61K31/53
- IPC: A61K31/53 ; A61K31/535 ; A61K31/55 ; A61K31/54 ; A61K31/554 ; C07D403/04 ; C07D279/10 ; C07D267/02 ; C07D243/08 ; C07D417/04 ; C07D413/04
Abstract:
The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents.
Public/Granted literature
- US20100197654A1 TRIAZINE KINASE INHIBITORS Public/Granted day:2010-08-05
Information query
